Drug-Releasing Stent Helps Diabetics

Sirolimus-eluting stent improves outcomes for diabetics undergoing angioplasty

MONDAY, Oct. 3 (HealthDay News) -- Sirolimus-eluting stents work better than a bare stent when it comes to preventing restenosis in diabetic patients after angioplasty, according to a study published in Circulation: Journal of the American Heart Association.

Manel Sabate, M.D., Ph.D., of San Carlos University Hospital in Madrid, Spain and colleagues randomized 160 patients to receive sirolimus-eluting stents (80 patients, 111 lesions) or standard stent implantation (80 patients, 110 lesions).

Target lesion revascularization and major adverse cardiac event rates were 31.3% and 7.3% in the sirolimus group compared with 36.3% and 11.3% with standard stents. The researchers found similar results after sirolimus-eluting stent implantation in non-insulin and insulin-requiring patients.

"This randomized trial demonstrated that sirolimus stent implantation is safe and efficacious in reducing both angiographic and clinical parameters of restenosis compared with standard stents in diabetic patients with de novo coronary stenoses," the researchers conclude.

The study was supported by a grant from the Spanish Society of Cardiology.

Full Text (payment may be required)

Physician's Briefing